Prosecution Insights
Last updated: August 17, 2026

Ipsen Biopharm Limited

9 pending office actions • 4 art units • 7 examiners • 0 of 9 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days

Portfolio Summary

9
Total Pending OAs
8
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

0
Overdue
0
Due this week
0
Due this month
2
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

3
Hard (33%)
4
Medium (44%)
2
Easy (22%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only1 (11%)
Double-patenting only2 (22%)
Double-patenting + other3 (33%)
Multi-statute (no §101)3 (33%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

9
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

90 h
Manual time on pending OAs
18 h
Time saved (low, 20%)
31 h
Time saved (mid, 35%)
0.8 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
DUFFY, PATRICIA ANN 2 52.7% +34.2%
DAVIS, RUTH A 2 60.7% +31.2%
OGUNBIYI, OLUWATOSIN A 1 63.7% +41.5%
GRASER, JENNIFER E 1 76.5% +23.6%
SWIFT, CANDICE LEE 1 57.4% +36.7%
PAGUIO FRISING, MICHELLE F 1 70.8% +40.3%
BREEN, KIMBERLY CATHERINE 1 24.4% +56.7%

Hard Cases (4)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.

App #TitleExaminerDue in
17759674 TREATMENT OF SKIN CONDITIONS DAVIS, RUTH A 40d
19423511 CHIMERIC NEUROTOXINS DUFFY, PATRICIA ANN
19341888 CHIMERIC NEUROTOXINS DUFFY, PATRICIA ANN
18552599 Clostridial Neurotoxins Comprising an Exogenous Activation Loop BREEN, KIMBERLY CATHERINE

Interview Candidates (9)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
18096899 TREATMENT OF MODERATE TO VERY SEVERE GLABELLAR LINES AND LATERAL CANTHAL LINES DAVIS, RUTH A 34d
17759674 TREATMENT OF SKIN CONDITIONS DAVIS, RUTH A 40d
19423511 CHIMERIC NEUROTOXINS DUFFY, PATRICIA ANN
19341888 CHIMERIC NEUROTOXINS DUFFY, PATRICIA ANN
18711074 TREATMENT OF PAIN OGUNBIYI, OLUWATOSIN A
18711047 TREATMENT OF VISCERAL PAIN GRASER, JENNIFER E
18690378 Modified Bont/A for Use in the Treatment of Cervical Dystonia SWIFT, CANDICE LEE
18552457 CATALYTICALLY INACTIVE CLOSTRIDIAL NEUROTOXINS FOR THE TREATMENT OF PAIN & INFLAMMATORY DISORDERS PAGUIO FRISING, MICHELLE F

Top Art Units

Art UnitApps
1645 4
1657 2
1699 2
1651 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
19423511 CHIMERIC NEUROTOXINS DUFFY, PATRICIA ANN 1645 §102§103§112Other Non-Final OA Pending Dec 17, 2025
19341888 CHIMERIC NEUROTOXINS DUFFY, PATRICIA ANN 1645 §103§112Other Non-Final OA Pending Sep 26, 2025
18711074 TREATMENT OF PAIN OGUNBIYI, OLUWATOSIN A 1645 DP Non-Final OA Pending May 16, 2024
18711047 TREATMENT OF VISCERAL PAIN GRASER, JENNIFER E 1645 §103 Non-Final OA Pending May 16, 2024
18690378 Modified Bont/A for Use in the Treatment of Cervical Dystonia SWIFT, CANDICE LEE 1657 DP Non-Final OA Pending Mar 08, 2024
18552457 CATALYTICALLY INACTIVE CLOSTRIDIAL NEUROTOXINS FOR THE TREATMENT OF PAIN & INFLAMMATORY DISORDERS PAGUIO FRISING, MICHELLE F 1651 §102§103DP Non-Final OA Pending Sep 26, 2023
18552599 Clostridial Neurotoxins Comprising an Exogenous Activation Loop BREEN, KIMBERLY CATHERINE 1657 §103§112DP Non-Final OA Pending Sep 26, 2023
18096899 TREATMENT OF MODERATE TO VERY SEVERE GLABELLAR LINES AND LATERAL CANTHAL LINES DAVIS, RUTH A 1699 §112DPOther Final Rejection 34d Pending Jan 13, 2023
17759674 TREATMENT OF SKIN CONDITIONS DAVIS, RUTH A 1699 §102§103§112Other Non-Final OA 40d Pending Jul 28, 2022

Managing Ipsen Biopharm Limited's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month